NFE2L2 and cancer: At the molecular level, in response to Ru-bdcurc treatment, cancer cells activated NRF2 and BiP pathways whose pharmacologic inhibition increased Ru-bdcurc-induced cell death, suggesting that they acted as death resistant mechanisms to the drug.